524 related articles for article (PubMed ID: 33741405)
21. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC.
Hložek T; Uttl L; Kadeřábek L; Balíková M; Lhotková E; Horsley RR; Nováková P; Šíchová K; Štefková K; Tylš F; Kuchař M; Páleníček T
Eur Neuropsychopharmacol; 2017 Dec; 27(12):1223-1237. PubMed ID: 29129557
[TBL] [Abstract][Full Text] [Related]
23. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure.
Miller S; Daily L; Leishman E; Bradshaw H; Straiker A
Invest Ophthalmol Vis Sci; 2018 Dec; 59(15):5904-5911. PubMed ID: 30550613
[TBL] [Abstract][Full Text] [Related]
24. The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model.
Cherniakov I; Izgelov D; Domb AJ; Hoffman A
Eur J Pharm Sci; 2017 Nov; 109():21-30. PubMed ID: 28736128
[TBL] [Abstract][Full Text] [Related]
25. Cannabidiol and Delta-9-Tetrahydrocannabinol Interactions in Male and Female Rats With Persistent Inflammatory Pain.
Britch SC; Craft RM
J Pain; 2023 Jan; 24(1):98-111. PubMed ID: 36122809
[TBL] [Abstract][Full Text] [Related]
26. [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain].
Clermont-Gnamien S; Atlani S; Attal N; Le Mercier F; Guirimand F; Brasseur L
Presse Med; 2002 Nov; 31(39 Pt 1):1840-5. PubMed ID: 12496714
[TBL] [Abstract][Full Text] [Related]
27. Acute and chronic effects of cannabidiol on Δ⁹-tetrahydrocannabinol (Δ⁹-THC)-induced disruption in stop signal task performance.
Jacobs DS; Kohut SJ; Jiang S; Nikas SP; Makriyannis A; Bergman J
Exp Clin Psychopharmacol; 2016 Oct; 24(5):320-330. PubMed ID: 27690502
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid tetrad effects of oral Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in male and female rats: sex, dose-effects and time course evaluations.
Moore CF; Weerts EM
Psychopharmacology (Berl); 2022 May; 239(5):1397-1408. PubMed ID: 34652500
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of recombinant human T-type calcium channels by Delta9-tetrahydrocannabinol and cannabidiol.
Ross HR; Napier I; Connor M
J Biol Chem; 2008 Jun; 283(23):16124-34. PubMed ID: 18390906
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
31. Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model.
Eeswara A; Pacheco-Spiewak A; Jergova S; Sagen J
PLoS One; 2023; 18(3):e0282920. PubMed ID: 36913400
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.
Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS
Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290
[TBL] [Abstract][Full Text] [Related]
33. Opioid and cannabinoid synergy in a mouse neuropathic pain model.
Kazantzis NP; Casey SL; Seow PW; Mitchell VA; Vaughan CW
Br J Pharmacol; 2016 Aug; 173(16):2521-31. PubMed ID: 27278681
[TBL] [Abstract][Full Text] [Related]
34. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
[TBL] [Abstract][Full Text] [Related]
35. Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action.
Mlost J; Bryk M; Starowicz K
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33238607
[TBL] [Abstract][Full Text] [Related]
36. A protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation.
Solowij N; Broyd SJ; van Hell HH; Hazekamp A
BMC Pharmacol Toxicol; 2014 Oct; 15():58. PubMed ID: 25319497
[TBL] [Abstract][Full Text] [Related]
37. Antinociceptive and Immune Effects of Delta-9-Tetrahydrocannabinol or Cannabidiol in Male Versus Female Rats with Persistent Inflammatory Pain.
Britch SC; Goodman AG; Wiley JL; Pondelick AM; Craft RM
J Pharmacol Exp Ther; 2020 Jun; 373(3):416-428. PubMed ID: 32179573
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of escalating cannabinoid doses in healthy cats.
Kulpa JE; Paulionis LJ; Eglit GM; Vaughn DM
J Feline Med Surg; 2021 Dec; 23(12):1162-1175. PubMed ID: 33769105
[TBL] [Abstract][Full Text] [Related]
39. Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.
Bansal S; Maharao N; Paine MF; Unadkat JD
Drug Metab Dispos; 2020 Oct; 48(10):1008-1017. PubMed ID: 32587099
[TBL] [Abstract][Full Text] [Related]
40. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
